Granted Patent B2

US 12,571,053 · App. 18/985,984 · Granted Mar 10, 2026

Inventors: Stefanie Ann Ward Mortimer (Morgan Hill, CA); AmirAli Talasaz (Atherton, CA); Darya Chudova (Los Altos, CA); Helmy Eltoukhy (Atherton, CA)

Assignee: Guardant Health, Inc.

C12Q1/6886C12M1/00C12M1/34C12Q1/6806C12Q1/6855C12Q1/6869G01N33/57557G16B20/20G16B30/10G16H50/20G16H50/30C12Q2600/118C12Q2600/154C12Q2600/156C12Q2600/158C12Q2600/166

Abstract

Claims (36)

1 . A method for detecting a presence or absence of residual disease in a subject, the method comprising:

(a) providing a sample from the subject comprising cell-free deoxyribonucleic acid (cfDNA) molecules;

(b) enriching cfDNA molecules or amplicons thereof from the sample, or a portion thereof, using sequence capture for a sequencing panel of genes or genomic regions to generate the sequencing panel, wherein the sequencing panel:

(i) is at least 150 kb,

(ii) comprises a plurality of genes or genomic regions having CpG islands which are differentially methylated regions,

(iii) comprises a plurality of genes or genomic regions known to be associated with one or more cancers,

(iv) comprises a subpanel for identifying tissue of origin,

wherein the subject previously received a treatment for cancer and the sample was obtained from the subject after the treatment;

(c) sequencing a plurality of enriched cfDNA molecules or enriched amplicons thereof from the sequencing panel to generate sequencing data; and

(d) determining methylation profiles of the cfDNA molecules from the sequencing data, detecting a presence or absence of one or more genetic variants in cfDNA molecules in the sample, and determining the tissue of origin of the cfDNA molecules to detect the presence or absence of residual disease in the subject.

2 . The method of claim 1 , wherein the sample is or is derived from a blood sample of the subject.

3 . The method of claim 1 , wherein the method comprises isolating methylated cfDNA molecules prior to enriching.

4 . The method of claim 1 , wherein adaptors are ligated to the cfDNA molecules prior to enriching.

5 . The method of claim 4 , wherein the adaptors comprise molecular barcodes.

6 . The method of claim 4 , wherein the ligation conditions comprise the use of over a 10×, over 20×, over 40×, over 60×, or over 80× molar excess of adaptors.

7 . The method of claim 1 , wherein the enriching comprises a differential tiling of the oligonucleotide probes.

8 . The method of claim 1 , wherein one or more regions comprise one or more sequences selected from the group consisting of exons, introns, promoters, 3′ untranslated regions, 5′ untranslated regions, splice sites, enhancers, and CpG islands.

9 . The method of claim 8 , wherein the at least one genomic region is a transcription start site in a promoter region of a tumor suppressor gene.

10 . The method of claim 1 , wherein enriched cfDNA molecules or amplicons thereof are amplified prior to sequencing.

11 . The method of claim 1 , wherein the sequencing is massively parallel sequencing that sequences at least 10 million polynucleotide molecules.

12 . The method of claim 11 , wherein the sequencing data comprises at least 1 billion, 1.1 billion, 1.2 billion, 1.5 billion, 2 billion, 2.5 billion, 3 billion, 3.5 billion, 4 billion, 4.5 billion, 5 billion, 5.5 billion, 6 billion, 6.5 billion, 7 billion, 8 billion, 9 billion or 10 billion base pairs.

13 . The method of claim 1 , wherein a read budget is selected that identifies the total number of base reads to be allocated to the sample, wherein the sample comprises a predetermined amount of DNA.

14 . The method of claim 1 , wherein the sequencing is performed at a depth of at least 50,000 reads per base, at least 100,000 reads per base, or at least 120,000 reads per base.

15 . The method of claim 14 , wherein the reads per base represent at least 5,000 original cfDNA molecules in the sample.

16 . The method of claim 1 , wherein the subject has previously received surgical treatment, radiation treatment, chemotherapy, targeted cancer therapeutics or a cancer immunotherapy.

17 . The method of claim 1 , wherein the subject does not have a cancer that is detectable by imaging methods.

18 . The method of claim 17 , wherein the imaging method is positron emission tomography scan, magnetic resonance imaging, X-ray, computerized axial tomography scan, ultrasound, or a combination thereof.

19 . The method of claim 1 , wherein the cancer is colorectal cancer, ovarian cancer, lung cancer, pancreatic cancer, or liver cancer.

20 . The method of claim 19 , wherein the cancer is detected at a specificity of at least 80% or greater, and wherein the sequencing panel is selected to detect the cancer at a positive predictive value (PPV) of at least 60%.

21 . The method of claim 1 , wherein sequence reads from the sequencing data are mapped to a reference sequence.

22 . The method of claim 1 , wherein the one or more genetic variants is a single nucleotide variant (SNV) or an insertion or deletion (indel).

23 . The method of claim 22 , wherein the detecting one or more genetic variants in the cfDNA molecules comprises determining a consensus sequence from sequence reads obtained from the sequence data to reduce errors from amplification or sequencing.

24 . The method of claim 23 , wherein the consensus sequence is performed on a molecule-by-molecule basis or a base-by-base basis.

25 . The method of claim 23 , wherein the consensus sequence is based on assessing probabilities of each of the potential nucleotides based on observed sequence output and the sequencing and amplification error profiles characteristics of an individual sample, a batch of sample, or a reference set of samples.

26 . The method of claim 23 , wherein molecular barcodes are used to group the sequencing reads into families derived from original individual cfDNA molecules, wherein the consensus sequence is generated for the family either on a molecule-by-molecule basis or a base-by-base basis.

27 . The method of claim 1 , wherein a frequency of nucleotides in the sample is determined by comparing it to a frequency of germline DNA from the subject.

Assignments (1)

Continuity (17)

References Cited (202)